Angiodynamics Inc. (ANGO)
AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants John Young - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2026 First Quarter Earnings Call.
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.11 per share a year ago.
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones, and a balanced portfolio despite tariff headwinds.
AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul
AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. Recent results confirm an inflection point: MedTech sales grew 19.5% in FY25, adjusted EBITDA turned positive, and the company now boasts a strong net cash balance sheet. Favorable sector trends, regulatory wins, and unique product positioning (Auryon, AlphaVac, NanoKnife) underpin robust growth prospects and expanding addressable markets.
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.
AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q4 2025 Earnings Conference Call July 15, 2025 8:00 AM ET Company Participants James C. Clemmer - CEO, President & Director Stephen A.
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.06 per share a year ago.
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
